Summary
41.57 -0.39(-0.93%)05/08/2024
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.46 | -1.36 | -16.33 | -6.28 | 10.19 | -10.82 | 31.55 | 79.32 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 41.96 | |
| Open | 43.21 | |
| High | 43.32 | |
| Low | 41.48 | |
| Volume | 657,737 | |
| Change | -1.06 | |
| Change % | -2.46 | |
| Avg Volume (20 Days) | 637,290 | |
| Volume/Avg Volume (20 Days) Ratio | 1.03 | |
| 52 Week Range | 31.52 - 54.98 | |
| Price vs 52 Week High | -23.68% | |
| Price vs 52 Week Low | 33.12% | |
| Range | -2.89 | |
| Gap Up/Down | 0.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,455 | |
| EBIDTA | -380,151,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.2400 | |
| WallStreet Target Price | 142.00 | |
| Book Value | 13.7380 | |
| Earnings Per Share | -5.3210 | |
| EPS Estimate Current Quarter | -1.4100 | |
| EPS Estimate Next Quarter | -1.5000 | |
| EPS Estimate Current Year | -6.2900 | |
| EPS Estimate Next Year | -5.7100 | |
| Diluted EPS (TTM) | -5.3210 | |
| Revenues | ||
| Profit Marging | -0.9889 | |
| Operating Marging (TTM) | -1.0437 | |
| Return on asset (TTM) | -0.1704 | |
| Return on equity (TTM) | -0.4445 | |
| Revenue TTM | 359,559,008 | |
| Revenue per share TTM | 5.3810 | |
| Quarterly Revenue Growth (YOY) | 0.0020 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -147,183,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.6870 | |
| Revenue Enterprise Value | 12.8401 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 68,162,200 | |
| Shares Float | 64,730,939 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.49 | |
| Institutions (%) | 99.62 | |
05/03 13:26 EST - Zacks Investment Research
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
05/02 21:01 EST - Zacks Investment Research
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/02 18:11 EST - Zacks Investment Research
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $2.33 per share a year ago.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $2.33 per share a year ago.
04/25 16:30 EST - GlobeNewsWire
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
04/16 12:35 EST - Zacks Investment Research
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
04/12 16:22 EST - GlobeNewsWire
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.
02/27 16:30 EST - GlobeNewsWire
Ultragenyx to Participate at Investor Conferences in March
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Â Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
Ultragenyx to Participate at Investor Conferences in March
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Â Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
02/16 08:56 EST - Zacks Investment Research
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
02/15 23:55 EST - Seeking Alpha
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
02/15 19:01 EST - Zacks Investment Research
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/15 18:11 EST - Zacks Investment Research
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compares to loss of $2.16 per share a year ago.
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compares to loss of $2.16 per share a year ago.
02/08 16:00 EST - GlobeNewsWire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023.
02/08 11:06 EST - Zacks Investment Research
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
01/09 19:34 EST - Zacks Investment Research
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
Ultragenyx Pharmaceutical Inc. (RARE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RARE's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
Ultragenyx Pharmaceutical Inc. (RARE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RARE's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
01/08 13:32 EST - Zacks Investment Research
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
01/04 09:47 EST - Zacks Investment Research
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
01/02 16:05 EST - GlobeNewsWire
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 PM PT.
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 PM PT.
01/02 11:16 EST - Zacks Investment Research
Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?
The mean of analysts' price targets for Ultragenyx (RARE) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?
The mean of analysts' price targets for Ultragenyx (RARE) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
11/20 16:30 EST - GlobeNewsWire
Ultragenyx to Participate at Investor Conferences in November
6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences.
Ultragenyx to Participate at Investor Conferences in November
6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences.
11/02 22:29 EST - Seeking Alpha
Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Dae Gon Ha - Stifel Michael Riad - Morgan Stanley Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Maury Raycroft - Jefferies Yaron Werber - TD Cowen Laura Chico - Wedbush. Operator Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call.
Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Dae Gon Ha - Stifel Michael Riad - Morgan Stanley Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Maury Raycroft - Jefferies Yaron Werber - TD Cowen Laura Chico - Wedbush. Operator Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call.